Compare · BSX vs SWAV
BSX vs SWAV
Side-by-side comparison of Boston Scientific Corporation (BSX) and Shockwave Medical Inc. (SWAV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and SWAV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX carries a market cap of $66.41B.
- BSX has hit the wire 11 times in the past 4 weeks while SWAV has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 21 for SWAV).
- Company
- Boston Scientific Corporation
- Shockwave Medical Inc.
- Price
- -
- -
- Market cap
- $66.41B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 21
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Shockwave Medical Inc.
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.
Latest BSX
- SVP, Chief HR Officer O'Sullivan Miriam converted options into 3,871 shares and covered exercise/tax liability with 1,872 shares, increasing direct ownership by 11% to 19,565 units (SEC Form 4)
- Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
- SEC Form 10-Q filed by Boston Scientific Corporation
- SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
- Boston Scientific downgraded by TD Cowen with a new price target
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- Boston Scientific downgraded by Oppenheimer
- Boston Scientific downgraded by Analyst with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific announces results for third quarter 2026
Latest SWAV
- Sonder Capital Closes its Second Fund and Announces Participation from Major Healthcare Systems
- Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
- Bruker Appoints Laura Francis to its Board of Directors
- Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner
- SEC Form 15-12G filed by Shockwave Medical Inc.
- Francis Laura returned 4,784 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Moll Frederic H returned 287,521 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Papiernik Antoine returned 34,913 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Sainz Maria returned 5,328 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form S-8 POS filed by Shockwave Medical Inc.